Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

Inclusion Criteria: * Aged 2 months (60-70 days) on the day of inclusion into the study * Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or more * Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation * Able to attend all planned clinic appointment and obey and follow all study instructions Exclusion Criteria: * Taking part in another clinical trial during the 4 weeks before the first trial vaccination * Have plans to take part in another clinical trial d during this trial period * Inborn or acquired decreased body natural defense, undertaking treatment that can reduce body's natural defense such as cancer drugs, radiation in the past six months or long term corticosteroid treatment * Systemic reaction to any vaccine component or history of life-threatening reaction to study vaccine or any vaccine with the same ingredient(s) * Prolonged or long time illness that could interfere with study or full participation * Received blood or blood-derived products since birth * Received any vaccine in the 4 weeks before the first trial vaccination is given (except BCG and hepatitis B) * Have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination is given (except DTacP) * Previous vaccination against the poliomyelitis infection with the trial vaccine or another vaccine * History of poliomyelitis infection (confirmed either by symptoms, blood or other laboratory test) * Clinical or serological evidence of systemic illness including hepatitis B, hepatitis C or Human immunodeficiency virus (HIV) * Bleeding disorder or a low platelet which do not allow vaccination into the muscle * Had seizures in the past * Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion